Dragon Pharma Launches 13 New Peptides — November 2025
Dragon Pharma has expanded its peptide range with 13 new compounds launched in November 2025 — the largest single catalogue expansion in the brand's history. The new additions span six functional categories: HPG axis and hormonal support, immune modulation, longevity and mitochondrial function, weight management, Khavinson bioregulators, and GH secretagogues. All products are independently third-party tested for compound identity, concentration accuracy and purity.
HPG Axis and Hormonal Support
Kisspeptin 10mg — GPR54 receptor agonist and master regulator of the HPG axis, operating above GnRH in the reproductive endocrine hierarchy. Kisspeptin neurons in the hypothalamus are the primary activators of GnRH pulse release — making Kisspeptin the most upstream peptide intervention for LH, FSH and testosterone recovery. Clinical applications include hypogonadism evaluation, fertility protocols and post-cycle HPG axis restoration. The pulsatile administration requirement — kisspeptin must be dosed to mimic endogenous GnRH pulsatility to avoid receptor desensitisation — distinguishes it mechanistically from standard PCT SERMs.
Testagen 20mg — Khavinson tetrapeptide bioregulator for testicular tissue. Works through epigenetic DNA demethylation in Leydig cells, reactivating steroidogenic gene expression suppressed by age or AAS-mediated atrophy. Distinct mechanism from HCG (LH receptor stimulation) — Testagen works at the genetic level to restore cellular function rather than stimulating production through an exogenous LH signal.
Immune Support
Thymosin Alpha-1 10mg — Zadaxin (thymalfasin), approved in over 40 countries for hepatitis B, hepatitis C, and immunodeficiency. The most clinically validated immune-modulating peptide available — activates T-cells, NK cells and dendritic cells through Toll-like receptor 7 and 9 signalling. Used in oncology supportive care, post-viral immune recovery and as general immune optimisation support. The only peptide in the Dragon Pharma range with an FDA Orphan Drug designation and extensive Phase III human clinical data.
Longevity and Mitochondrial Function
NAD+ 500mg — Injectable nicotinamide adenine dinucleotide. NAD+ is the universal electron carrier and sirtuin/PARP substrate central to DNA repair, mitochondrial function and circadian rhythm regulation. Parenteral (injectable) NAD+ bypasses the enzymatic conversion required for oral precursors (NMN, NR), producing immediate systemic NAD+ elevation. Clinical applications include energy metabolism support, neurocognitive function and cellular ageing intervention.
MOTS-c 10mg — Mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. MOTS-c activates AMPK and downstream metabolic pathways including GLUT4 glucose transport upregulation and fatty acid oxidation. Clinical interest centres on its role in exercise mimicry, insulin sensitivity improvement and metabolic disease. Unique as the only known mitochondrially-encoded peptide with hormone-like systemic effects.
Weight Management
Tirzepatide 10mg — High-dose vial of the dual GLP-1/GIP receptor agonist. The 10mg vial enables maintenance-phase dosing for established Tirzepatide protocols. Phase III SURMOUNT data demonstrates 20-22% body weight reduction at maximum dose — the highest documented weight loss of any approved obesity pharmacotherapy. The 10mg vial complements the existing Tirzepatide 5mg initiation vial.
Adipotide (FTPP) 10mg — Prohibitin-targeting proapoptotic peptide. Adipotide selectively targets and destroys blood vessels supplying white adipose tissue through prohibitin receptor binding on adipose vasculature. In primate studies (Kolonin et al., 2004), subcutaneous Adipotide produced significant visceral and subcutaneous fat reduction through vascular apoptosis — a mechanism entirely distinct from GLP-1/appetite suppression or lipolysis. Currently preclinical in humans.
Khavinson Bioregulators
Ovagen 20mg — Khavinson tetrapeptide bioregulator for liver and gastrointestinal tissue. Works through epigenetic DNA demethylation in hepatocytes and GI epithelial cells, reactivating gene expression programmes suppressed by age, toxic exposure or disease. Distinct from conventional hepatoprotective agents (TUDCA, UDCA, NAC) — Ovagen acts at the genetic level to restore cellular function rather than buffering oxidative stress or bile acid cycling.
L-Carnitine 500mg Injectable — Parenteral L-Carnitine for mitochondrial long-chain fatty acid transport. Injectable administration bypasses GI absorption limitations, producing higher plasma carnitine levels than equivalent oral dosing. Primary application: fat oxidation support during caloric deficit and endurance performance enhancement.
GH Secretagogue Additions
Ipamorelin + Tesamorelin 10mg blend — Pre-combined GHRP + GHRH formulation. Tesamorelin (FDA-approved for HIV-associated lipodystrophy) provides GHRH receptor activation with GH pulse amplification and documented visceral fat reduction as a secondary effect. Combined with Ipamorelin's mildest GHRP profile, this blend provides the complete dual-mechanism GH secretagogue protocol with a specific lean body composition application distinguishing it from the standard CJC+Ipamorelin combination.